Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Cozzi Lepri

Showing results (61-70 of 244) with videos related to

Pageof 25
Sort By:
Journal of the International AIDS Society|November 15, 2014
Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replicationCarmela Pinnetti, Patrizia Lorenzini, Alessandro Cozzi-Lepri, et al.
Antiviral Therapy|May 14, 2003
Changes in viral load in people with virological failure who remain on the same HAART regimenAlessandro Cozzi-Lepri, Andrew N Phillips, Veronica Miller, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 29, 2004
Prevalence of HIV-1 primary drug resistance in seroconverters of the ICoNA cohort over the period 1996-2001Michela Violin, Rossella Velleca, Alessandro Cozzi-Lepri, et al.
Plos One|May 13, 2016
Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral TherapyBirgit Grund, Jason V Baker, Steven G Deeks, et al.
Plos One|June 28, 2016
Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation CohortAntonella d'Arminio Monforte, Alessandro Cozzi-Lepri, Franco Maggiolo, et al.
Plos One|December 8, 2015
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C VirusCristina Mussini, Patrizia Lorenzini, Massimo Puoti, et al.
The Lancet. Infectious Diseases|June 27, 2009
Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysisRavindra K Gupta, Andrew Hill, Anthony W Sawyer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 18, 2017
Brief Report: Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological SuppressionNicola Gianotti, Giulia Marchetti, Andrea Antinori, et al.
AIDS (London, England)|January 16, 2008
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDAWendy P Bannister, Lidia Ruiz, Alessandro Cozzi-Lepri, et al.
Journal of Global Antimicrobial Resistance|November 19, 2022
Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failuresRoberta Gagliardini, Patrizia Lorenzini, Alessandro Cozzi-Lepri, et al.
Pageof 25

Showing results (61-70 of 244) with videos related to

Sort By:
Pageof 25
Journal of the International AIDS Society|November 15, 2014
Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replicationCarmela Pinnetti, Patrizia Lorenzini, Alessandro Cozzi-Lepri, et al.
Antiviral Therapy|May 14, 2003
Changes in viral load in people with virological failure who remain on the same HAART regimenAlessandro Cozzi-Lepri, Andrew N Phillips, Veronica Miller, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 29, 2004
Prevalence of HIV-1 primary drug resistance in seroconverters of the ICoNA cohort over the period 1996-2001Michela Violin, Rossella Velleca, Alessandro Cozzi-Lepri, et al.
Plos One|May 13, 2016
Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral TherapyBirgit Grund, Jason V Baker, Steven G Deeks, et al.
Plos One|June 28, 2016
Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation CohortAntonella d'Arminio Monforte, Alessandro Cozzi-Lepri, Franco Maggiolo, et al.
Plos One|December 8, 2015
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C VirusCristina Mussini, Patrizia Lorenzini, Massimo Puoti, et al.
The Lancet. Infectious Diseases|June 27, 2009
Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysisRavindra K Gupta, Andrew Hill, Anthony W Sawyer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 18, 2017
Brief Report: Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological SuppressionNicola Gianotti, Giulia Marchetti, Andrea Antinori, et al.
AIDS (London, England)|January 16, 2008
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDAWendy P Bannister, Lidia Ruiz, Alessandro Cozzi-Lepri, et al.
Journal of Global Antimicrobial Resistance|November 19, 2022
Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failuresRoberta Gagliardini, Patrizia Lorenzini, Alessandro Cozzi-Lepri, et al.
Pageof 25